1360364-21-1 Usage
Description
Tert-butyl octahydropyrrolo[3,4-b]morpholine-6-carboxylate is a carboxylate ester derivative with the molecular formula C14H25NO3. It features a unique structure comprising a fused pyrrolidine and morpholine ring system, which endows it with potential for interactions with biological targets. This chemical compound is commonly utilized in pharmaceutical research as a building block for the synthesis of various molecules, particularly for the development of potential drug candidates.
Uses
Used in Pharmaceutical Research:
Tert-butyl octahydropyrrolo[3,4-b]morpholine-6-carboxylate is used as a building block for the synthesis of various molecules in pharmaceutical research. Its unique structure allows it to be a versatile component in the development of potential drug candidates.
Used in Drug Discovery and Development:
Due to its diverse chemical properties, tert-butyl octahydrolo[3,4-b]morpholine-6-carboxylate is studied for its potential applications in drug discovery and development. Its ability to interact with biological targets makes it a promising candidate for the creation of new therapeutic agents.
Check Digit Verification of cas no
The CAS Registry Mumber 1360364-21-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,6,0,3,6 and 4 respectively; the second part has 2 digits, 2 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1360364-21:
(9*1)+(8*3)+(7*6)+(6*0)+(5*3)+(4*6)+(3*4)+(2*2)+(1*1)=131
131 % 10 = 1
So 1360364-21-1 is a valid CAS Registry Number.
1360364-21-1Relevant articles and documents
HPK1 ANTAGONISTS AND USES THEREOF
-
, (2021/03/19)
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
4-quinazoline amine derivatives and their use
-
, (2017/01/31)
A 4-quinazoline amine derivative as represented by formula (1), a pharmaceutical composition comprising the derivative, and an application thereof in preparing medicine for curing cancer. The cancer is a drug-resistant cancer, preferably a cancer resisting an EGFR reversible inhibitor, and more preferably, a cancer resisting gefitinib, erlotinib or lapatinib; alternatively, the cancer carries EGFR mutation.